Publications in collaboration with researchers from Harvard Medical School (22)

2023

  1. Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care

    Seminars in Hematology

  2. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia

    Seminars in Hematology

  3. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

    Seminars in Hematology

  4. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

    Seminars in Hematology

  5. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

  6. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

    Seminars in Hematology

  7. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials

    Seminars in Hematology

2022

  1. High frequency of central nervous system involvement in transformed Waldenstrom € macroglobulinemia

    Blood Advances

  2. IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S385

2021

  1. Denosumab compared with zoledronic acid on PFS in multiple myeloma: Exploratory results of an international phase 3 study

    Blood Advances, Vol. 5, Núm. 3, pp. 725-736

  2. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e119-e130

2020

  1. A prognostic index predicting survival in transformed Waldenström macroglobulinemia

    Haematologica, Vol. Online ahead of print

  2. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study

    Blood, Vol. 136, Núm. 18, pp. 2038-2050

  3. Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia

    British Journal of Haematology, Vol. 189, Núm. 6, pp. 1165-1170

  4. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial

    Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018

2016

  1. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): A multi-institutional retrospective study

    British Journal of Haematology, Vol. 172, Núm. 5, pp. 709-715

  2. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia

    British Journal of Haematology, Vol. 175, Núm. 1, pp. 77-86

  3. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

    Blood, Vol. 128, Núm. 10, pp. 1321-1328

2014

  1. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma

    Blood, Vol. 123, Núm. 26, pp. 4120-4131

  2. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

    Blood, Vol. 124, Núm. 9, pp. 1404-1411